Methodologic Issues in the Validation of Putative Biomarkers and Surrogate Endpoints in Treatment Evaluation for Systemic Lupus Erythematosus

Publisher： Bentham Science Publishers

E-ISSN： 2212-3873|9|1|108-112

ISSN： 1871-5303

Source： Endocrine, Metabolic & Immune Disorders-Drug Targets (Formerly Current Drug Targets - Immune, Endocrine & Metabolic Disorders), Vol.9, Iss.1, 2009-03, pp. : 108-112

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Dehydroepiandrosterone for the treatment of systemic lupus erythematosus

By van Vollenhoven Ronald F  

Expert Opinion on Pharmacotherapy, Vol. 3, Iss. 1, 2002-01 ,pp. : 23-31

Informa Healthcare

Access to resources Recommend Favorite

Treatment Options for Juvenile-Onset Systemic Lupus Erythematosus

By Carreño L.   López-Longo F.J.   González C.M.   Monteagudo I.  

Pediatric Drugs, Vol. 4, Iss. 4, 2002-01 ,pp. : 241-256

Adis International

Access to resources Recommend Favorite

New therapies for the treatment of systemic lupus erythematosus

By Gullick Dr Nicola   D’Cruz Dr David  

Expert Opinion on Therapeutic Patents, Vol. 17, Iss. 3, 2007-03 ,pp. : 299-313

Informa Healthcare

Access to resources Recommend Favorite

An Insight on the Pathogenesis and Treatment of Systemic Lupus Erythematosus

By  

Endocrine, Metabolic & Immune Disorders-Drug Targets (Formerly Current Drug Targets - Immune, Endocrine & Metabolic Disorders), Vol. 18, Iss. 2, 2018-02 ,pp. : 110-123

Bentham Science Publishers

Access to resources Recommend Favorite

Monoclonal Antibodies in the Treatment of Systemic Lupus Erythematosus

By  

Current Drug Targets, Vol. 10, Iss. 1, 2009-01 ,pp. : 26-37

Bentham Science Publishers

Access to resources Recommend Favorite